BFC Planning’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$56.2K Buy
864
+375
+77% +$25.9K ﹤0.01% 1493
2026
Q2
$32.4K Sell
489
-100
-17% -$5.86K ﹤0.01% 1765
2026
Q1
$31.9K Sell
589
-66
-10% -$3.68K ﹤0.01% 1513
2025
Q4
$36.7K Buy
655
+44
+7% +$2.28K ﹤0.01% 1493
2025
Q3
$29.3K Buy
+611
New +$27.3K ﹤0.01% 1396

Other funds holding XPH

BFC Planning's XPH Position: Q3 2026 in Review

BFC Planning increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 77% in Q3 2026, buying an estimated $25.9K and bringing the position to 864 shares worth $56.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1493.

BFC Planning first reported a position in XPH in Q3 2025 and has held it in 5 quarters since. 101 funds tracked by Wall St. Rank hold XPH as of Q3 2026.

  • BFC Planning held 864 shares of State Street SPDR S&P Pharmaceuticals ETF worth $56.2K as of Q3 2026.
  • BFC Planning bought 375 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2026, an estimated $25.9K.
  • State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1493 holding.
  • BFC Planning first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2025 and has held it in 5 quarters since.
  • 101 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.